Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.09 - $4.8 $1,440 - $76,824
16,005 Added 89.14%
33,959 $3,000
Q3 2022

Nov 14, 2022

SELL
$0.14 - $4.8 $9,996 - $342,720
-71,400 Reduced 79.91%
17,954 $3,000
Q2 2022

Aug 15, 2022

BUY
$0.88 - $1.73 $865 - $1,700
983 Added 1.11%
89,354 $79,000
Q1 2022

May 16, 2022

BUY
$1.14 - $2.09 $4,560 - $8,360
4,000 Added 4.74%
88,371 $110,000
Q4 2021

Feb 14, 2022

BUY
$1.67 - $2.76 $47,595 - $78,660
28,500 Added 51.01%
84,371 $165,000
Q3 2021

Nov 15, 2021

SELL
$2.62 - $3.45 $2,358 - $3,105
-900 Reduced 1.59%
55,871 $153,000
Q2 2021

Aug 16, 2021

BUY
$1.96 - $3.15 $33,851 - $54,403
17,271 Added 43.72%
56,771 $179,000
Q1 2021

May 17, 2021

BUY
$1.89 - $2.96 $74,655 - $116,920
39,500 New
39,500 $84,000

Others Institutions Holding VTGN

# of Institutions
1
Shares Held
27.1K
Call Options Held
0
Put Options Held
0

About VistaGen Therapeutics, Inc.


  • Ticker VTGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 206,836,000
  • Market Cap $517M
  • Description
  • VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...
More about VTGN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.